RETROSPECTIVE EVALUATION OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN PATIENTS WITH GLIOBLASTOMA COMPARING 6 VS 12 CYCLES OF ADJUVANT TEMOZOLOMIDE

被引：0
|
作者：
Perez, D. Martinez [1 ]
Mendez, B. Deben [1 ]
Roldan, M. Rodriguez [1 ]
Botella, M. Garrido [1 ]
Cuesta, J. Garcia [1 ]
Barbas, J. Pedregosa [1 ]
Aguirre, Y. Vilches [1 ]
Marin, V. Martinez [1 ]
机构：
[1] Hosp La Paz, Madrid, Spain
来源：
NEURO-ONCOLOGY | 2022年 / 24卷
关键词：
D O I：
10.1093/neuonc/noac174.265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P11.76.A
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Extended cycles of adjuvant temozolomide improves survival outcomes in glioblastoma: a retrospective analysis
    Xu, Hao
    Yu, Shengnan
    Wang, Chunyan
    Hu, Yue
    Ren, Qinglan
    Jiang, Lihao
    [J]. JOURNAL OF CANCER METASTASIS AND TREATMENT, 2024, 8
  • [2] Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity
    Gruber, M. L.
    Raza, S.
    Gruber, D.
    Narayana, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Glioblastoma: A Retrospective Analysis of the Role of the Maximal Surgical Resection on Overall Survival and Progression Free Survival
    Polonara, Gabriele
    Aiudi, Denis
    Iacoangeli, Alessio
    Raggi, Alessio
    Ottaviani, Matteo Maria
    Antonini, Ruggero
    Iacoangeli, Maurizio
    Dobran, Mauro
    [J]. BIOMEDICINES, 2023, 11 (03)
  • [4] Improved survival of patients with glioblastoma multiforme by temozolomide as adjuvant therapy: A retrospective cohort study
    Wang, T. H.
    Wei, K. C.
    Wang, J. D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A56 - A56
  • [5] Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Clarke, Jennifer L.
    Ennis, Michele M.
    Yung, W. K. Alfred
    Chang, Susan M.
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    DeAngelis, Lisa M.
    Robins, H. Ian
    Lieberman, Frank S.
    Fine, Howard A.
    Abrey, Lauren
    Gilbert, Mark R.
    Mehta, Minesh
    Kuhn, John G.
    Aldape, Kenneth D.
    Lamborn, Kathleen R.
    Prados, Michael D.
    [J]. NEURO-ONCOLOGY, 2011, 13 (10) : 1118 - 1124
  • [6] IS SURGERY AT PROGRESSION A PROGNOSTIC MARKER FOR IMPROVED 6-MONTH PROGRESSION-FREE SURVIVAL OR OVERALL SURVIVAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA?
    Clarke, J. L.
    Ennis, Michele M.
    Lamborn, Kathleen R.
    Prados, Michael D.
    [J]. NEURO-ONCOLOGY, 2010, 12 : 69 - 69
  • [7] Progression-free (PFS) and Overall Survival (OS) after adjuvant Therapy RT/RCT of Patients with Glioblastoma: Retrospective Analysis of 114 consecutive Patients
    Hass, P.
    Machalett, M.
    Woerdehoff, H.
    Walke, M.
    Gademann, G.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 : 79 - 79
  • [8] Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Polley, Mei-Yin C.
    Lamborn, Kathleen R.
    Chang, Susan M.
    Butowski, Nicholas
    Clarke, Jennifer L.
    Prados, Michael
    [J]. NEURO-ONCOLOGY, 2010, 12 (03) : 274 - 282
  • [9] Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
    Harshit Arora
    Marco Mammi
    Naisargi Manishkumar Patel
    Dea Zyfi
    Hema Reddy Dasari
    Ismael Yunusa
    Thomas Simjian
    Timothy R. Smith
    Rania A. Mekary
    [J]. Journal of Neuro-Oncology, 2024, 166 : 17 - 26
  • [10] Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
    Arora, Harshit
    Mammi, Marco
    Patel, Naisargi Manishkumar
    Zyfi, Dea
    Dasari, Hema Reddy
    Yunusa, Ismael
    Simjian, Thomas
    Smith, Timothy R.
    Mekary, Rania A.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2024, 166 (01) : 17 - 26
12345